NCT07743918Recruiting
Vitamin D Status and Clinical Outcomes in Locally Advanced Cervical Cancer
Pretreatment Vitamin D Status and Clinical Outcomes in Patients With Locally Advanced Cervical Cancer Undergoing Definitive Chemoradiotherapy
Source: ClinicalTrials.gov · Last updated 4 Aug 2026
Brief summary (registry, in English)
Background. Definitive chemoradiotherapy represents the standard therapeutic approach for the management of locally advanced cervical cancer. Vitamin D plays an important role in the regulation of cellular growth and differentiation, immune system function, and the modulation of inflammatory processes. Hypovitaminosis D may be associated with the development of cervical cancer, whereas its impact on the effects of oncological treatment remains insufficiently elucidated. The aim of this study is to investigate the predictive significance of vitamin D in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy. Methods. This study is designed as a clinical, observational, prospective cohort study. Patients with locally advanced cervical cancer undergoing definitive chemoradiotherapy at the Clinic for Radiation Oncology, University Clinical Center Kragujevac, will be enrolled. Vitamin D concentrations will be measured before the initiation of treatment in both serum and cervical lavage samples. Baseline vitamin D levels will be analyzed in relation to treatment outcome and the occurrence of acute radiation toxicity. In addition, vitamin D concentrations will be evaluated in the context of clinical and morphological parameters, therapeutic response, and treatment-related toxicity. Expected Results. This study will enable an assessment of the actual significance of pretreatment vitamin D concentrations in serum and cervical lavage as a potential novel biomarker in relation to chemoradiosensitivity and/or chemoradioresistance of cervical cancer, as well as the response of organs at risk, in patients with locally advanced disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 13 Jul 2026
- Start date
- 1 Jan 2026
- Primary completion date
- 10 Jan 2028
- Lead sponsor
- University of Kragujevac
- Diseases
- Cervical cancer
- NCT number
- NCT07743918
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Jan 2026 to the primary completion date, 10 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous or synchronous diagnosis of another pelvic or abdominal malignancy.
- Previous chemotherapy.
- Previous radiotherapy.
- Previous treatment with immune checkpoint inhibitors.
Other illness
- Failure to attend scheduled follow-up visits.
Age
- Age under 18 years.
Other
- Pregnancy or lactation.
- Current or recent vitamin D supplementation.
- Interrupted oncological treatment.
- Incomplete medical documentation.
Who the study is looking for
- Female patients aged 18 to 80 years.
- Histopathologically confirmed cervical cancer.
- Locally advanced disease, FIGO 2018 stage IIB to IVA.
- Eastern Cooperative Oncology Group performance status 0-1.
- Planned treatment with definitive concurrent chemoradiotherapy.
- Signed informed consent.
- Ability to comply with study procedures and follow-up visits.
Age in the registry: 18 years to 80 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Clinical Center Kragujevac Coordinator of this site? Confirm its status | Kragujevac | Serbia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.